You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

platinum resistant primary ovarian cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Biopsy
  • Pegylated SN-38 Conjugate PLX038
  • Rochester, Minnesota
    Mayo Clinic
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Ovarian Cancer, Epithelial Trial in Nanjing (Envafolimab, Lenvatinib, VP-16)

Not yet recruiting
  • Ovarian Cancer, Epithelial
  • Nanjing, Jiangsu, China
    Zhongda Hospital
Jun 13, 2022

Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer Trial in Houston (Paclitaxel/Bev (control), Paclitaxel/Bev + ZA

Recruiting
  • Epithelial Ovarian
  • +2 more
  • Paclitaxel/Bev (control)
  • Paclitaxel/Bev + ZA (experimental)
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma Trial in Bethesda, Boston (Biopsy,

Recruiting
  • Advanced Fallopian Tube Carcinoma
  • +21 more
  • Biopsy
  • +2 more
  • Bethesda, Maryland
  • +2 more
Jan 25, 2023

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • New Haven, Connecticut
  • +1 more
Jan 11, 2023

Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)

Completed
  • Advanced Ovarian Cancer
  • Sabadell, Barcelona, Spain
  • +7 more
Jan 25, 2023

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Canada, United States (Nemvaleukin

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +2 more
  • Nemvaleukin and Pembrolizumab Combination
  • +6 more
  • Ventura, California
  • +7 more
Aug 5, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in Santa Monica, Pittsburgh, Houston (TTI-622, Pegylated Liposomal

Recruiting
  • Ovarian Cancer
  • +5 more
  • TTI-622
  • Pegylated Liposomal Doxorubicin
  • Santa Monica, California
  • +4 more
Jul 26, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant

Recruiting
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • +5 more
  • Etigilimab
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 22, 2021

Ovarian Cancer Trial in Beijing (BD0801, Paclitaxel, Placebo)

Recruiting
  • Ovarian Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Nov 24, 2021

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022